MCP
GPCR icon

Maso Capital Partners’s Structure Therapeutics GPCR Stock Holding History

Maso Capital Partners’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,000
Closed -$270K – 46
2025
Q2 		$270K Buy
+13,000
New +$286K 0.48% 13

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Maso Capital Partners's GPCR Position: Q3 2025 in Review

Maso Capital Partners sold out of Structure Therapeutics (GPCR) in Q3 2025, closing a stake of 13,000 shares — an estimated $270K sold.

Maso Capital Partners first reported a position in GPCR in Q2 2025 and held it in 1 quarter. The position peaked at $270K in Q2 2025. 156 funds tracked by Wall St. Rank hold GPCR as of Q3 2025.

  • Maso Capital Partners reported no remaining Structure Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Maso Capital Partners sold 13,000 Structure Therapeutics shares in Q3 2025, an estimated $270K.
  • Maso Capital Partners first reported a position in Structure Therapeutics in Q2 2025 and held it in 1 quarter.
  • Maso Capital Partners's Structure Therapeutics position peaked at $270K in Q2 2025.
  • 156 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2025.

Based on Maso Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.